Pernix Therapeutics Holdings Inc

Pernix Therapeutics — Investor Presentation (January 2011)

25 slides from Pernix Therapeutics's investor presentation, Jan 20, 2011

  1. Slide 1: Investor Presentation January 2011

    Slide 1: Investor Presentation January 2011

    Investor Presentation January 2011

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    The following presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward looking statements, whi

  3. Slide 3: Pernix Today

    Slide 3: Pernix Today

    Pernix Today Integrated Specialty Pharmaceutical Business Gross sales of $38.3 million in 2009, three-year CAGR of 41.5%; Profitable and generating cash flow Strong IP-Driven Operating Model Focus on branded pediatric products with high gross margins / low cap ex requirements; 23 trademark interests

  4. Slide 4: Corporate Structure

    Slide 4: Corporate Structure

    Corporate Structure Pernix Therapeutics, LLC (Branded Pharmaceutical Products) Macoven Pharmaceuticals, LLC (Generic business) Wholly-owned subsidiary Gaine, Inc. (Intellectual Property Assets) Wholly-owned subsidiary Pernix Therapeutics Holdings, Inc. (Corporate)

  5. Slide 5: Recent Milestones

    Slide 5: Recent Milestones

    ■ Received FDA Approval for Human Head Lice Treatment in January 2011 o Product available in the first half of 2011 ■ Formed Joint Venture with UK Development Company in December 2010 o $1.5 million investment to fund late-stage development of theobromine-based treatment for persistent cough ■ Acqui

  6. Slide 6: Strategic Plan

    Slide 6: Strategic Plan

    Strategic Plan Grow sales of Cedax and other existing products Identify new collaborations; Accretive acquisitions Develop new products; Expand into new markets beyond pediatrics Near-Term Medium-Term Long-Term Utilize sales force of 55 representatives in pediatrics Consider product expansion by acq

  7. Slide 7: Current Product Portfolio

    Slide 7: Current Product Portfolio

    Products Active Categories Aldex Family Cold/Cough BC1036** Antitussive Brovex Family Cold/Cough Cedax Antibiotic Natroba Head Lice Pediatex Family Cold/Cough QuinZyme* Cardiovascular ReZyst IM Gastro-Probiotic Z-Cof Family Cold/Cough Zema-Pak Corticosteroid Therapy Current Product Portfolio * Partn

  8. Slide 8: Current/Future Sales Force

    Slide 8: Current/Future Sales Force

    Current/Future Sales Force 2009 Total Employees: ~80 2010 Sales Representatives: 55 2010 Q4 Sales Force Additions: 10-12 (Goal) 2011 and beyond - increase reach to mid-decile prescribers with increased frequency

  9. Slide 9: Sales Force Efficiency

    Slide 9: Sales Force Efficiency

    Sales Force Efficiency • Pernix sales force averaged almost 560 RX’s per rep for the Pediatex TD Product in the 4 th month of the launch Launch of Pediatex Launch of Brovex • Pernix acquired the Brovex product line for $450,000 in June 2009 • Following the product launch in August 2009, the Pernix s

  10. Slide 10: Cedax

    Slide 10: Cedax

    o Only competing third generation cephalosporin product generated nearly $100 million of sales at retail in 2009 o Opportunity to expand into oral solid market through co-promotion efforts ■ Indicated Treatment for Middle Ear Infections o Antibiotics are promotion sensitive and highly prescribed in

  11. Slide 11: Natroba

    Slide 11: Natroba

    ■ Pernix expects to receive payments between 35%-42% of net sales proceeds ■ Received FDA Approval for Use in Patients Ages 4 and Up in January o According to two phase III studies, the product was shown as significantly more effective in eliminating head lice than permethrin 1% (Nix, AAP recommende

  12. Slide 12: Growth Strategy

    Slide 12: Growth Strategy

    Growth Strategy

  13. Slide 13: Macoven Pharmaceuticals

    Slide 13: Macoven Pharmaceuticals

    § Profitable Generics Division o Provides opportunity for alternative revenue stream, authorized generics o Transaction funded with initial draw on line of credit § Launched 11 Generic Pharmaceutics in 2010 o Includes five authorized generic equivalents of Pernix branded products, as of September 30

  14. Slide 14: Development Pipeline

    Slide 14: Development Pipeline

    § Identify Partners to Efficiently and Cost Effectively Bring New Products to Market § Rights to 8 Product Candidates as of August 16, 2010 o Four antitussive product candidates o Two product candidates to treat symptoms associated with dermatitis o One product candidate in our Z-COF product line o

  15. Slide 15: Natural Cough Suppressant

    Slide 15: Natural Cough Suppressant

    § Joint Venture Formed with SEEK (UK) to Develop Codeine-Free Cough Suppressant (BC1036) o Pernix believes this antitussive candidate has potential to address the need for a safer and more effective, non-opioid treatment for persistent cough o Pernix contributed $1.5 million and its theobromine IP (

  16. Slide 16: Management Team

    Slide 16: Management Team

    Title Cooper Collins President and Chief Executive Officer Tracy Clifford Chief Financial Officer, Secretary and Treasurer Robert Cline Vice President, Operations and Supply Chain Management Mike Venters Vice President, Corporate Development Beth DeVille Vice President, Sales and Marketing Managemen

  17. Slide 17: Market Opportunity

    Slide 17: Market Opportunity

    Market Opportunity

  18. Slide 18: Cough and Cold Market

    Slide 18: Cough and Cold Market

    § Cold/Cough Sector-Annual Sales in Excess of $2 billion 1 § Over 35.9 Million People have Seasonal Allergic Rhinitis, Accounting for $4.5 Billion Spent on Direct Care 2 § Allergic Disease Affects More Than 20% of the Population and is the 3rd Leading Chronic Disease Among Children Under 18 Years of

  19. Slide 19: Antibiotics and Lice Market

    Slide 19: Antibiotics and Lice Market

    § Over 5 Million Cases of Middle Ear Infections Occur Annually in Children, Which Resulted in 10 Million Antibiotic Prescriptions per Year 1 § Middle Ear Infections are the Most Common Illnesses Experienced by Babies and Young Children o Number one cause of consultations with physicians § The U.S. C

  20. Slide 20: Financials

    Slide 20: Financials

    Financials

  21. Slide 21: Profitable Growth

    Slide 21: Profitable Growth

    Historical sales growth driven by increasing demand for Brovex, Pediatex, Aldex and Z-Cof products Profitable Growth Consistent growth in earnings resulting from focus on high margin product sales and lean operating structure

  22. Slide 22: Condensed Income Statement

    Slide 22: Condensed Income Statement

    ($, in millions except per share data) Three Months Ended September 30 Nine Months Ended September 30 2010 2009 2010 2009 Net Sales 7.8 5.8 21.0 19.6 Gross Profit 6.3 4.1 17.7 15.4 Selling, General & Administrative Expense 3.3 2.3 9.4 7.4 Income from Operations 3.2 1.1 7.9 6.6 Net Income 2.4 1.1 7.8

  23. Slide 23: Financial Position

    Slide 23: Financial Position

    As of September 30, 2010 ($, in millions) Cash and Cash Equivalents 8.2 Working Capital 5.6 Total Assets 36.6 Total Debt 2.2 For the Nine Months Ended September 30, 2010 ($, in millions) Cash Flow from Operations 2.1 CapEx 0.1 Free Cash Flow 2.0 Financial Position Definition : We define free cash fl

  24. Slide 24: Investment Considerations

    Slide 24: Investment Considerations

    Investment Considerations Integrated Specialty Pharmaceutical Business Gross sales of $38.3 million in 2009, three-year CAGR of 41.5%; Profitable and generating cash flow Strong IP-Driven Operating Model Focus on branded pediatric products with high gross margins / low cap ex requirements; 23 tradem

  25. Slide 25: Pernix Therapeutics Holdings, Inc. Thank You

    Slide 25: Pernix Therapeutics Holdings, Inc. Thank You

    Pernix Therapeutics Holdings, Inc. NYSE Amex: PTX Cooper Collins, President & CEO 33219 Forest West Drive Magnolia, TX 77354 www.pernixtx.com Thank You

Source: SEC EDGAR · 8-K filed Jan 20, 2011

More decks from Pernix Therapeutics Holdings Inc